Efficacy and Safety Results of Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: 16-Week Results From SPROUT, a Phase 3, Randomized, Controlled Study

Main Article Content

Loretta Fiorillo
Stollery Children’s Hospital, University of Alberta, Edmonton, Alberta, Canada

Emily Becker
Driscoll Children’s Hospital, Corpus Christi, TX, USA

Raul de Lucas
Hospital Universitario La Paz – PPDS, Madrid, Spain

Anna Belloni-Fortina
Azienda Ospedale Università Padova, Padova, Italy

Susana Armesto
Hospital Universitario Marques de Valdecilla, Santander, Spain

Peter Maes
Amgen Inc., Thousand Oaks, CA, USA

Rajneet Oberoi
Amgen Inc., Thousand Oaks, CA, USA

Maria Paris
Amgen Inc., Thousand Oaks, CA, USA

Wendy Zhang
Amgen Inc.

Zuoshun Zhang
Amgen Inc., Thousand Oaks, CA, USA

Lisa Arkin
University of Wisconsin School of Medicine and Public Health, Madison, WI, USA

Keywords

Apremilast, Plaque Psoriasis, Pediatrics

References

1. Papp K, et al. J Am Adad Dermatol. 2015;73:37–49.

2. Paul C, et al. Br J Dermatol. 2015;173:1387-1399.

Article Sidebar

Poster PDF
Published
Mar 13, 2023
DOI https://doi.org/10.25251/skin.7.supp.109

Article Details

How to Cite
Fiorillo, L., Becker, E., de Lucas, R., Belloni-Fortina, A., Armesto, S. ., Maes, P. ., Oberoi, R. ., Paris, M. ., Zhang, W., Zhang, Z. ., & Arkin, L. . (2023). Efficacy and Safety Results of Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: 16-Week Results From SPROUT, a Phase 3, Randomized, Controlled Study. SKIN The Journal of Cutaneous Medicine, 7(2), s109. https://doi.org/10.25251/skin.7.supp.109
Issue
Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Section
Posters from 2023 WCH Dermatology Conference: Psoriasis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.